{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T21:17:48Z","timestamp":1791321468189,"version":"4.3.1"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,10,25]],"date-time":"2023-10-25T00:00:00Z","timestamp":1698192000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,10,25]],"date-time":"2023-10-25T00:00:00Z","timestamp":1698192000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Virol J"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Ethiopia is among the highly HIV-affected countries, with reported 12,000 and 12,000 AIDS-related deaths and incidents as per reports from 2021. Although the country has made\u00a0a promising\u00a0progress in antiretroviral therapy, recent studies have\u00a0indicated that pretreatment drug resistance (PDR) is alarmingly increasing, which\u00a0has become a challenge for the effectiveness of HIV treatment. Epidemiologic data on PDR is necessary to help establish ART regimens with good efficacy. Thus, this systematic review aimed to determine the trend analysis of PDR among ART-na\u00efve individuals along with HIV variant dynamics in Ethiopia.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Method<\/jats:title>\n                <jats:p>HIV-1 pol sequences from studies conducted between 2003 and 2018 among ART-na\u00efve Ethiopian individuals were retrieved from GenBank and analyzed for the presence of PDR mutations (PDRM) along with the analysis of HIV-1 variant dynamics. The Calibrated Population Resistance (CPR) tool Version 8.1 and the\u00a0REGA HIV-1 Subtyping Tool Version 3 were used to determine the PDRM and HIV-1 genetic diversity, respectively.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Result<\/jats:title>\n                <jats:p>We identified nine studies and analyzed 1070 retrieved HIV-1 pol sequences in this systematic review. The pooled prevalence of PDR was 4.8% (51\/1070), including 1.4% (15\/1070), 2.8% (30\/1070), and 0.8% (9\/1070) for nucleoside reverse transcriptase inhibitor (NRTI), non-NRTI (NNRTI), and protease inhibitor (PI) resistance, respectively. NRTI and NNRTI concurrent PDRM were observed among 0.2% (2\/799) of the analyzed sequences. The overall PDR prevalence has been increasing over the years. Though the prevalence of the NNRTI, NRTI, and PI PDR also increased over the years, the NNRTI increment was more pronounced than the others, reaching 7.84% in 2018 from 2.19% in 2003. The majority (97%; 1038\/1070) of the genetic diversity was HIV-1 subtype C virus, followed by subtype C\u2019 (2%; 20\/1038) and other subtypes (1%; 10\/1038).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>According to this systematic review, the overall pooled prevalence of PDR is low. Despite the low prevalence, there has been an increasing trend of PDR over the years, which implies the need for routine surveillance of PDRMs along with preventive measures. Hence, this supports the recently endorsed transition of ART regimens from NNRTI to integrase strand transfer inhibitor-based regimens recommended by\u00a0the WHO. In addition, this finding underscores the need for routine baseline genotypic drug resistance testing for all newly diagnosed HIV-infected patients before initiating treatment to halt the upward trend of PDR.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12985-023-02205-w","type":"journal-article","created":{"date-parts":[[2023,10,25]],"date-time":"2023-10-25T12:02:33Z","timestamp":1698235353000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Trends in HIV-1 pretreatment drug resistance and HIV-1 variant dynamics among antiretroviral therapy-naive Ethiopians from 2003 to 2018: a pooled sequence analysis"],"prefix":"10.1186","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7909-7719","authenticated-orcid":false,"given":"Mulugeta","family":"Kiros","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1260-1108","authenticated-orcid":false,"given":"Sirak","family":"Biset","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birhane","family":"Gebremariam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gebrehiwet Tesfay","family":"Yalew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Woldaregay Erku","family":"Abegaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7153-4849","authenticated-orcid":false,"given":"Alene","family":"Geteneh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,10,25]]},"reference":[{"key":"2205_CR1","unstructured":"UNAIDS. UNAIDS Global AIDS Update. 2022."},{"key":"2205_CR2","unstructured":"UNAIDS. UNAIDS data 2022."},{"key":"2205_CR3","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1093\/infdis\/jiaa683","volume":"224","author":"S Bertagnolio","year":"2020","unstructured":"Bertagnolio S, Hermans L, Jordan MR, Avila-Rios S, Iwuji C, Derache A, et al. Clinical impact of pretreatment human immunodeficiency virus drug resistance in people initiating nonnucleoside reverse transcriptase inhibitor-containing antiretroviral therapy: a systematic review and meta-analysis. J Infect Dis. 2020;224:377\u201388.","journal-title":"J Infect Dis"},{"issue":"3","key":"2205_CR4","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1016\/S1473-3099(17)30702-8","volume":"18","author":"RK Gupta","year":"2018","unstructured":"Gupta RK, Gregson J, Parkin N, Haile-Selassie H, Tanuri A, Andrade Forero L, et al. HIV-1 drug resistance before initiation or re-initiation of first-line antiretroviral therapy in low-income and middle-income countries: a systematic review and meta-regression analysis. Lancet Infect Dis. 2018;18(3):346\u201355.","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"2205_CR5","doi-asserted-by":"publisher","first-page":"21140","DOI":"10.7448\/IAS.19.1.21140","volume":"19","author":"RS Boerma","year":"2016","unstructured":"Boerma RS, Boender TS, Sigaloff KC, de Wit TFR, van Hensbroek MB, Ndembi N, et al. High levels of pre-treatment HIV drug resistance and treatment failure in Nigerian children. J Int AIDS Soc. 2016;19(1):21140.","journal-title":"J Int AIDS Soc."},{"key":"2205_CR6","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/1476-072X-6-45","volume":"6","author":"H Kloos","year":"2007","unstructured":"Kloos H, Assefa Y, Adugna A, Mulatu MS, Mariam DH. Utilization of antiretroviral treatment in Ethiopia between February and December 2006: spatial, temporal, and demographic patterns. Int J Health Geogr. 2007;6:45.","journal-title":"Int J Health Geogr"},{"key":"2205_CR7","unstructured":"Federal Ministry of Health (FMOH). National guidelines for comprehensive HIV prevention, care and treatment. 2018."},{"issue":"1","key":"2205_CR8","doi-asserted-by":"publisher","first-page":"63","DOI":"10.4314\/ejhs.v27i1.7S","volume":"27","author":"D Fekade","year":"2017","unstructured":"Fekade D, Weldegebreal T, Teklu AM, Damen M, Abdella S, Baraki N, et al. Predictors of survival among adult Ethiopian patients in the national ART program at Seven University Teaching Hospitals: a prospective cohort study. Ethiop J Health Sci. 2017;27(1):63\u201371.","journal-title":"Ethiop J Health Sci"},{"issue":"10","key":"2205_CR9","doi-asserted-by":"publisher","first-page":"e0205446","DOI":"10.1371\/journal.pone.0205446","volume":"13","author":"DA Arimide","year":"2018","unstructured":"Arimide DA, Abebe A, Kebede Y, Adugna F, Tilahun T, Kassa D, et al. HIV-genetic diversity and drug resistance transmission clusters in Gondar, Northern Ethiopia, 2003\u20132013. PLoS ONE. 2018;13(10):e0205446.","journal-title":"PLoS ONE"},{"issue":"1","key":"2205_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12977-020-00542-0","volume":"17","author":"M Kiros","year":"2020","unstructured":"Kiros M, Alemayehu DH, Geberekidan E, Mihret A, Maier M, Abegaz WE, et al. Increased HIV-1 pretreatment drug resistance with consistent clade homogeneity among ART-naive HIV-1 infected individuals in Ethiopia. Retrovirology. 2020;17(1):1\u201310.","journal-title":"Retrovirology"},{"key":"2205_CR11","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1177\/135965350801302S04","volume":"13","author":"DE Bennett","year":"2008","unstructured":"Bennett DE, Myatt M, Bertagnolio S, Sutherland D, Gilks CF. Recommendations for surveillance of transmitted HIV drug resistance in countries scaling up antiretroviral treatment. Antivir Ther. 2008;13:25.","journal-title":"Antivir Ther"},{"key":"2205_CR12","unstructured":"Organization WH. HIV drug resistance report 2021. 2021."},{"issue":"11","key":"2205_CR13","first-page":"1778","volume":"43","author":"H Chen","year":"2022","unstructured":"Chen H, Zhou Y, Hao J, Zhang J, Hu J, Song C, et al. Effects of pretreatment HIV drug resistance on the virological response of HIV-infected patients after 3-year antiretroviral therapy. Zhonghua Liuxingbingxue Zazhi. 2022;43(11):1778\u201383.","journal-title":"Zhonghua Liuxingbingxue Zazhi"},{"key":"2205_CR14","doi-asserted-by":"publisher","first-page":"100238","DOI":"10.1016\/j.eclinm.2019.100238","volume":"18","author":"L Zuo","year":"2020","unstructured":"Zuo L, Liu K, Liu H, Hu Y, Zhang Z, Qin J, et al. Trend of HIV-1 drug resistance in China: a systematic review and meta-analysis of data accumulated over 17 years (2001\u20132017). EClinicalMedicine. 2020;18:100238.","journal-title":"EClinicalMedicine"},{"issue":"12","key":"2205_CR15","first-page":"3476","volume":"73","author":"L Rudovick","year":"2018","unstructured":"Rudovick L, Brauner JM, Englert J, Seemann C, Plugaru K, Kidenya BR, et al. Prevalence of pretreatment HIV drug resistance in Mwanza, Tanzania. J Antimicrob Chemother. 2018;73(12):3476\u201381.","journal-title":"J Antimicrob Chemother"},{"issue":"18","key":"2205_CR16","first-page":"100239","volume":"14","author":"I Beck","year":"2020","unstructured":"Beck I, Levine M, McGrath C, Bii S, Milne R, Kingoo J. Pre-treatment HIV-drug resistance associated with virologic outcome of first-line NNRTI-antiretroviral therapy: a cohort study in Kenya. EClin Med. 2020;14(18):100239.","journal-title":"EClin Med"},{"key":"2205_CR17","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.eclinm.2019.03.006","volume":"9","author":"B Chimukangara","year":"2019","unstructured":"Chimukangara B, Lessells RJ, Rhee S-Y, Giandhari J, Kharsany AB, Naidoo K, et al. Trends in pretreatment HIV-1 drug resistance in antiretroviral therapy-naive adults in South Africa, 2000\u20132016: a pooled sequence analysis. EClinical Med. 2019;9:26\u201334.","journal-title":"EClinical Med"},{"issue":"7","key":"2205_CR18","doi-asserted-by":"publisher","first-page":"e0235958","DOI":"10.1371\/journal.pone.0235958","volume":"15","author":"J Fokam","year":"2020","unstructured":"Fokam J, Takou D, Teto G, Nforbih SE, Kome OP, Santoro MM, et al. Pre-treatment drug resistance and HIV-1 genetic diversity in the rural and urban settings of Northwest-Cameroon. PLoS ONE. 2020;15(7):e0235958.","journal-title":"PLoS ONE"},{"issue":"11","key":"2205_CR19","doi-asserted-by":"publisher","first-page":"3137","DOI":"10.1093\/jac\/dky278","volume":"73","author":"N Taffa","year":"2018","unstructured":"Taffa N, Roscoe C, Sawadogo S, De Klerk M, Baughman AL, Wolkon A, et al. Pretreatment HIV drug resistance among adults initiating ART in Namibia. J Antimicrob Chemother. 2018;73(11):3137\u201342.","journal-title":"J Antimicrob Chemother"},{"issue":"1","key":"2205_CR20","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s12981-019-0219-1","volume":"16","author":"LD Bahls","year":"2019","unstructured":"Bahls LD, Canezin PH, Reiche EMV, Fernandez JCC, Dias JRC, Meneguetti VAF, et al. Moderate prevalence of HIV-1 transmitted drug resistance mutations in southern Brazil. AIDS Res Ther. 2019;16(1):4.","journal-title":"AIDS Res Ther"},{"issue":"9","key":"2205_CR21","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1111\/hiv.12640","volume":"19","author":"B Rossetti","year":"2018","unstructured":"Rossetti B, Di Giambenedetto S, Torti C, Postorino M, Punzi G, Saladini F, et al. Evolution of transmitted HIV-1 drug resistance and viral subtypes circulation in Italy from 2006 to 2016. HIV Med. 2018;19(9):619\u201328.","journal-title":"HIV Med"},{"issue":"3","key":"2205_CR22","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1111\/hiv.12414","volume":"18","author":"A Tostevin","year":"2017","unstructured":"Tostevin A, White E, Dunn D, Croxford S, Delpech V, Williams I, et al. Recent trends and patterns in HIV-1 transmitted drug resistance in the United Kingdom. HIV Med. 2017;18(3):204\u201313.","journal-title":"HIV Med"},{"issue":"1","key":"2205_CR23","doi-asserted-by":"publisher","first-page":"71","DOI":"10.3390\/v14010071","volume":"14","author":"T Wagner","year":"2021","unstructured":"Wagner T, Zuckerman NS, Halperin T, Chemtob D, Levy I, Elbirt D, et al. Epidemiology and transmitted HIV-1 drug resistance among treatment-na\u00efve individuals in Israel, 2010\u20132018. Viruses. 2021;14(1):71.","journal-title":"Viruses."},{"issue":"1","key":"2205_CR24","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1186\/s12879-021-05854-w","volume":"21","author":"X Pang","year":"2021","unstructured":"Pang X, Tang K, He Q, Huang J, Fang N, Zhou X, et al. HIV drug resistance and HIV transmission risk factors among newly diagnosed individuals in Southwest China. BMC Infect Dis. 2021;21(1):160.","journal-title":"BMC Infect Dis"},{"issue":"1","key":"2205_CR25","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1186\/s12985-021-01653-6","volume":"18","author":"Y Lan","year":"2021","unstructured":"Lan Y, Li L, He X, Hu F, Deng X, Cai W, et al. Transmitted drug resistance and transmission clusters among HIV-1 treatment-na\u00efve patients in Guangdong, China: a cross-sectional study. Virol J. 2021;18(1):181.","journal-title":"Virol J"},{"issue":"1","key":"2205_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12981-020-00282-3","volume":"17","author":"F Neuhann","year":"2020","unstructured":"Neuhann F, de Forest A, Heger E, Nhlema A, Scheller C, Kaiser R, et al. Pretreatment resistance mutations and treatment outcomes in adults living with HIV-1: a cohort study in urban Malawi. AIDS Res Ther. 2020;17(1):1\u20137.","journal-title":"AIDS Res Ther"},{"issue":"3","key":"2205_CR27","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1093\/jac\/dkz502","volume":"75","author":"M Mat\u00edas-Florentino","year":"2020","unstructured":"Mat\u00edas-Florentino M, Chaillon A, \u00c1vila-R\u00edos S, Mehta SR, Paz-Ju\u00e1rez HE, Becerril-Rodr\u00edguez MA, et al. Pretreatment HIV drug resistance spread within transmission clusters in Mexico City. J Antimicrob Chemother. 2020;75(3):656\u201367.","journal-title":"J Antimicrob Chemother"},{"issue":"11","key":"2205_CR28","doi-asserted-by":"publisher","first-page":"e0225251","DOI":"10.1371\/journal.pone.0225251","volume":"14","author":"CS Sebasti\u00e3o","year":"2019","unstructured":"Sebasti\u00e3o CS, Neto Z, de Jesus CS, Mirandela M, Jandondo D, Couto-Fernandez JC, et al. Genetic diversity and drug resistance of HIV-1 among infected pregnant women newly diagnosed in Luanda, Angola. PLoS ONE. 2019;14(11):e0225251.","journal-title":"PLoS ONE"},{"issue":"7","key":"2205_CR29","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1111\/j.1468-1293.2006.00404.x","volume":"7","author":"Margot N, Lu B, Cheng A, Miller M, Team S","year":"2006","unstructured":"Margot N, Lu B, Cheng A, Miller M, Team S. Resistance development over 144 weeks in treatment-naive patients receiving tenofovir disoproxil fumarate or stavudine with lamivudine and efavirenz in Study 903. HIV Med. 2006;7(7):442\u201350.","journal-title":"HIV Med"},{"key":"2205_CR30","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.ebiom.2017.03.024","volume":"18","author":"S-Y Rhee","year":"2017","unstructured":"Rhee S-Y, Varghese V, Holmes SP, Van Zyl GU, Steegen K, Boyd MA, et al. Mutational correlates of virological failure in individuals receiving a WHO-recommended tenofovir-containing first-line regimen: an international collaboration. EBioMed. 2017;18:225\u201335.","journal-title":"EBioMed"},{"issue":"18","key":"2205_CR31","doi-asserted-by":"publisher","first-page":"1850","DOI":"10.1056\/NEJMoa031772","volume":"350","author":"RM Gulick","year":"2004","unstructured":"Gulick RM, Ribaudo HJ, Shikuma CM, Lustgarten S, Squires KE, Meyer WA III, et al. Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection. N Engl J Med. 2004;350(18):1850\u201361.","journal-title":"N Engl J Med"},{"issue":"11","key":"2205_CR32","doi-asserted-by":"publisher","first-page":"4999","DOI":"10.1128\/JVI.75.11.4999-5008.2001","volume":"75","author":"L Bacheler","year":"2001","unstructured":"Bacheler L, Jeffrey S, Hanna G, D\u2019Aquila R, Wallace L, Logue K, et al. Genotypic correlates of phenotypic resistance to efavirenz in virus isolates from patients failing nonnucleoside reverse transcriptase inhibitor therapy. J Virol. 2001;75(11):4999\u20135008.","journal-title":"J Virol"},{"issue":"1","key":"2205_CR33","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1093\/jac\/dkt316","volume":"69","author":"GL Melikian","year":"2014","unstructured":"Melikian GL, Rhee S-Y, Varghese V, Porter D, White K, Taylor J, et al. Non-nucleoside reverse transcriptase inhibitor (NNRTI) cross-resistance: implications for preclinical evaluation of novel NNRTIs and clinical genotypic resistance testing. J Antimicrob Chemother. 2014;69(1):12\u201320.","journal-title":"J Antimicrob Chemother"},{"issue":"1","key":"2205_CR34","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1097\/QAI.0b013e31823df4da","volume":"59","author":"L Rimsky","year":"2012","unstructured":"Rimsky L, Vingerhoets J, Van Eygen V, Eron J, Clotet B, Hoogstoel A, et al. Genotypic and phenotypic characterization of HIV-1 isolates obtained from patients on rilpivirine therapy experiencing virologic failure in the phase 3 ECHO and THRIVE studies: 48-week analysis. JAIDS J Acquir Immune Defic Syndr. 2012;59(1):39\u201346.","journal-title":"JAIDS J Acquir Immune Defic Syndr"},{"issue":"3","key":"2205_CR35","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1128\/AAC.02403-13","volume":"58","author":"M-T Lai","year":"2014","unstructured":"Lai M-T, Feng M, Falgueyret J-P, Tawa P, Witmer M, DiStefano D, et al. In vitro characterization of MK-1439, a novel HIV-1 nonnucleoside reverse transcriptase inhibitor. Antimicrob Agents Chemother. 2014;58(3):1652\u201363.","journal-title":"Antimicrob Agents Chemother"},{"issue":"8","key":"2205_CR36","doi-asserted-by":"publisher","first-page":"3122","DOI":"10.1128\/AAC.48.8.3122-3126.2004","volume":"48","author":"S-Y Rhee","year":"2004","unstructured":"Rhee S-Y, Liu T, Ravela J, Gonzales MJ, Shafer RW. Distribution of human immunodeficiency virus type 1 protease and reverse transcriptase mutation patterns in 4,183 persons undergoing genotypic resistance testing. Antimicrob Agents Chemother. 2004;48(8):3122\u20136.","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"2205_CR37","doi-asserted-by":"publisher","first-page":"1512","DOI":"10.1128\/JVI.77.2.1512-1523.2003","volume":"77","author":"W Huang","year":"2003","unstructured":"Huang W, Gamarnik A, Limoli K, Petropoulos CJ, Whitcomb JM. Amino acid substitutions at position 190 of human immunodeficiency virus type 1 reverse transcriptase increase susceptibility to delavirdine and impair virus replication. J Virol. 2003;77(2):1512\u201323.","journal-title":"J Virol"},{"issue":"4","key":"2205_CR38","first-page":"559","volume":"30","author":"A Wensing","year":"2023","unstructured":"Wensing A, Calvez V, Ceccherini-Silberstein F, Charpentier C, G\u00fcnthard H, Paredes R, et al. 2022 update of the drug resistance mutations in HIV-1. Top Antivir Med. 2023;30(4):559\u201374.","journal-title":"Top Antivir Med"},{"issue":"1","key":"2205_CR39","doi-asserted-by":"publisher","first-page":"128","DOI":"10.3390\/v15010128","volume":"15","author":"A Appah","year":"2022","unstructured":"Appah A, Beelen CJ, Kirkby D, Dong W, Shahid A, Foley B, et al. Molecular epidemiology of HIV-1 in Ghana: subtype distribution, drug resistance and coreceptor usage. Viruses. 2022;15(1):128.","journal-title":"Viruses."},{"key":"2205_CR40","doi-asserted-by":"publisher","first-page":"104134","DOI":"10.1016\/j.meegid.2019.104134","volume":"78","author":"EN de Carvalho Lima","year":"2020","unstructured":"de Carvalho Lima EN, Lima RSA, Piqueira JRC, Sucupira MC, Camargo M, Galinskas J, et al. Evidence of genomic information and structural restrictions of HIV-1 PR and RT gene regions from individuals experiencing antiretroviral virologic failure. Infect Genet Evol. 2020;78:104134.","journal-title":"Infect Genet Evol"},{"issue":"5","key":"2205_CR41","doi-asserted-by":"publisher","first-page":"546","DOI":"10.3390\/pathogens11050546","volume":"11","author":"S-Y Rhee","year":"2022","unstructured":"Rhee S-Y, Boehm M, Tarasova O, Di Teodoro G, Abecasis AB, S\u00f6nnerborg A, et al. Spectrum of atazanavir-selected protease inhibitor-resistance mutations. Pathogens. 2022;11(5):546.","journal-title":"Pathogens"},{"issue":"1","key":"2205_CR42","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.jviromet.2007.05.009","volume":"145","author":"H Vermeiren","year":"2007","unstructured":"Vermeiren H, Van Craenenbroeck E, Alen P, Bacheler L, Picchio G, Lecocq P, et al. Prediction of HIV-1 drug susceptibility phenotype from the viral genotype using linear regression modeling. J Virol Methods. 2007;145(1):47\u201355.","journal-title":"J Virol Methods"},{"issue":"10","key":"2205_CR43","doi-asserted-by":"publisher","first-page":"4253","DOI":"10.1128\/AAC.00574-10","volume":"54","author":"S-Y Rhee","year":"2010","unstructured":"Rhee S-Y, Taylor J, Fessel WJ, Kaufman D, Towner W, Troia P, et al. HIV-1 protease mutations and protease inhibitor cross-resistance. Antimicrob Agents Chemother. 2010;54(10):4253\u201361.","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"2205_CR44","doi-asserted-by":"publisher","first-page":"697","DOI":"10.3390\/v14040697","volume":"14","author":"N Rana","year":"2022","unstructured":"Rana N, Singh AK, Shuaib M, Gupta S, Habiballah MM, Alkhanani MF, et al. Drug resistance mechanism of M46I-mutation-induced saquinavir resistance in HIV-1 protease using molecular dynamics simulation and binding energy calculation. Viruses. 2022;14(4):697.","journal-title":"Viruses"},{"issue":"9","key":"2205_CR45","doi-asserted-by":"publisher","first-page":"1992","DOI":"10.3390\/v14091992","volume":"14","author":"N Ismael","year":"2022","unstructured":"Ismael N, Wilkinson E, Mahumane I, Gemusse H, Giandhari J, Bauhofer A, et al. Molecular epidemiology and trends in HIV-1 transmitted drug resistance in mozambique 1999\u20132018. Viruses. 2022;14(9):1992.","journal-title":"Viruses"},{"issue":"12","key":"2205_CR46","doi-asserted-by":"publisher","first-page":"e0166305","DOI":"10.1371\/journal.pone.0166305","volume":"11","author":"K Steegen","year":"2016","unstructured":"Steegen K, Carmona S, Bronze M, Papathanasopoulos MA, van Zyl G, Goedhals D, et al. Moderate levels of pre-treatment HIV-1 antiretroviral drug resistance detected in the first south African national survey. PLoS ONE. 2016;11(12):e0166305.","journal-title":"PLoS ONE"},{"issue":"4","key":"2205_CR47","doi-asserted-by":"publisher","first-page":"594","DOI":"10.3390\/v13040594","volume":"13","author":"KK Seatla","year":"2021","unstructured":"Seatla KK, Maruapula D, Choga WT, Ntsipe T, Mathiba N, Mogwele M, et al. HIV-1 Subtype C drug resistance mutations in heavily treated patients failing integrase strand transfer inhibitor-based regimens in Botswana. Viruses. 2021;13(4):594.","journal-title":"Viruses."}],"container-title":["Virology Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12985-023-02205-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12985-023-02205-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12985-023-02205-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,17]],"date-time":"2024-01-17T21:38:28Z","timestamp":1705527508000},"score":1,"resource":{"primary":{"URL":"https:\/\/virologyj.biomedcentral.com\/articles\/10.1186\/s12985-023-02205-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,25]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["2205"],"URL":"https:\/\/doi.org\/10.1186\/s12985-023-02205-w","relation":{},"ISSN":["1743-422X"],"issn-type":[{"value":"1743-422X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,25]]},"assertion":[{"value":"29 May 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 October 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 October 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors have approved the manuscript for publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All the authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"243"}}